What is it about?
This publication is about the potential usage of the glycylcycline broad-spectrum antibiotic, tigecycline in the indication of severe Clostridium difficile infection (CDI)
Featured Image
Why is it important?
In a retrospective cohort study of 90 consecutive patients, we found that clinical cure and less CDI associated complication and sepsis might be associated with the usage of tigecycline compared to standard therapy (intravenous metronidazole and oral vancomycin)
Perspectives
As a clinician working in the field of infectious disease, I think that our preliminary results might shed light on alternative or salvage treatments for patients who are battling the most severe forms of CDI. Our final goal is to help fellow clinicians in their daily decision making and to inspire future prospective, large scale studies dealing with the therapy of severe CDI.
Dr. Balint Gergely Szabo
Joined Saint Stephan and Saint Ladislaus Hospital-Clinic
Read the Original
This page is a summary of: Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study, Clinical Microbiology and Infection, December 2016, Elsevier,
DOI: 10.1016/j.cmi.2016.08.017.
You can read the full text:
Resources
IV tigecycline scores as alternative C. difficile treatment
A conference coverage about the topic 1.
Tigecycline May Be an Alternative to Standard Therapy in Severe Clostridium difficile Infection: Presented at ECCMID
A conference coverage about the topic 2.
ECCMID2016
Congress abstract and presentation description in the ECCMID2016 e-Library
Contributors
The following have contributed to this page
